4:26
Making an IMPACT in ALL therapy: how can cure rates be improved?
David Marks
0:51
Nelarabine as first-line treatment for T-cell ALL: facing the problem up-front
David Marks
10:31
Recent subtypes of ALL: Ph-like ALL and ETP ALL
Anjali Advani et al.
0:49
The future of inhibiting Bcl2 for the treatment of T-ALL
Kim Kampen
1:07
The serine biosynthesis pathway and its role in T-ALL
Kim Kampen
1:22
Understanding the RPL10 R98S mutation in T-ALL
Kim Kampen
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals